Runhao Li
Higher Degree by Research Candidate
Adelaide Medical School
Faculty of Health and Medical Sciences
PhD, Molecular Oncology – The University of Adelaide
Dr Runhao Li is a molecular oncology researcher with a strong background in gene and cell therapy, tumour immunology, and translational cancer research. His doctoral work at the Basil Hetzel Institute for Translational Health Research focused on developing recombinant adeno-associated viral (rAAV) vectors and investigating how molecular and immune factors regulate tumour progression and therapeutic response.
Research interests:
- Gene and cell therapy for cancer and liver disease
- Tumour immune microenvironment and immune modulation
- Non-viral gene delivery and synthetic biology
- Biomarker discovery and translational medicine
- Integration of molecular, transcriptomic, and proteomic data
Technical expertise:
- Molecular cloning, vector engineering (rAAV, lentivirus)
- Flow cytometry, ELISA, qPCR, Western blot
- RNA-seq and transcriptomic data analysis using R
- Mammalian cell culture and functional immunoassays
- In vivo and ex vivo models of cancer immunotherapy
-
Appointments
Date Position Institution name 2021 - ongoing Postgraduate Research student Basil Hetzel Institute for Translational Health Research -
Language Competencies
Language Competency Chinese (Mandarin) Can read, write, speak and understand spoken English Can read, write, speak and understand spoken -
Education
Date Institution name Country Title 2022 University of Adelaide Australia PhD 2020 - 2021 University of Adelaide Australia Master 2014 - 2018 Liaoning University China Bachelor -
Research Interests
-
Journals
-
Preprint
Year Citation 2025 Rad, S. K., Yeo, K., Wu, F., Li, R., Nourmohammadi, S., Tomita, Y., . . . Smith, E. (2025). Systematic Review and Meta-Analysis of 16S rRNA and Cancer Microbiome Atlas Datasets to Characterize Microbiota Signatures in Normal Breast, Mastitis and Breast Cancer.
DOI2025 Kianpour Rad, S., Li, R., Yeo, K., Wu, F., Tomita, Y., Price, T., . . . Smith, E. (2025). Bacterial Infection and Their Cell Wall Ligands Differentially Modulate Doxorubicin Sensitivity in Triple‐Negative Breast Cancer Cells.
DOI2025 Rad, S. K., Li, R., Yeo, K., Cooksley, C., Shaghayegh, G., Vreugde, S., . . . Smith, E. (2025). Cell Line-Dependent Internalization, Persistence, and Immunomodulatory Effects of Staphylococcus aureus in Triple-Negative Breast Cancer.
DOI2024 Rad, S. K., Yeo, K., Li, R., Wu, F., Liu, S., Nourmohammadi, S., . . . Smith, E. (2024). Enhancement of Doxorubicin Efficacy by Bacopaside II in Triple-Negative Breast Cancer Cells.
DOI2024 Yeo, K., Wu, F., Li, R., Smith, E., Wormald, P. -J., Valentine, R., . . . Fenix, K. (2024). Is Short-Read 16S rRNA Sequencing of Oral Microbiome Sampling a Suitable Diagnostic Tool for Head and Neck Cancer?.
DOI2024 Li, R., Liu, S., Yeo, K., Edwards, S., Li, M. Y., Santos, R., . . . Smith, E. (2024). Circulating SFRP5 levels are elevated in colorectal cancer and correlate with overall survival in stage II-III disease.
DOI
Connect With Me
External Profiles
